Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP Strategy for Neovascular Age-Related Macular Degeneration
NCT07744204Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2026
- Primary completion
- Jul 2029
01
Overview
Randomised, open-label trial in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Total Number of Anti-VEGF Injections at 24 months. Planned start Aug 2026; status: not yet recruiting.
02
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07744204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744204.